Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Abstract Text:

Sun H Kim,Oxana Ivanova,Fahim A Abbasi,Cindy A Lamendola,Gerald M Reaven,Ira D Glick,

Switching antipsychotic regimen to agents with low weight gain potential has been suggested in patients who gain excessive weight on their antipsychotic therapy. In an open-label pilot study, we evaluated the metabolic and psychiatric efficacy of switching to aripiprazole in 15 (9 men, 6 women) outpatients with schizophrenia who had gained at least 10 kg on their previous antipsychotic regimen. Individuals had evaluation of glucose tolerance, insulin resistance (insulin suppression test), lipid concentrations, and psychiatric status before and after switching to aripiprazole for 4 months. A third of the individuals could not psychiatrically tolerate switching to aripiprazole. In the remaining individuals, psychiatric symptoms significantly improved with decline in Clinical Global Impression Scale (by 26%, P = 0.015) and Positive and Negative Syndrome Scale (by 22%, P = 0.023). Switching to aripiprazole did not alter weight or metabolic outcomes (fasting glucose, insulin resistance, and lipid concentrations) in the patients of whom 73% were insulin resistant and 47% had impaired or diabetic glucose tolerance at baseline. In conclusion, switching to aripiprazole alone does not ameliorate the highly prevalent metabolic abnormalities in the schizophrenia population who have gained weight on other second generation antipsychotic medications.

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Publishing Authors By Initials

SH Kim,O Ivanova,FA Abbasi,CA Lamendola,GM Reaven,ID Glick,

For similar pathological conditions, signs and symptoms: signs and symptoms: body weight: body weight changes: weight gain research abstracts see: pathological conditions, signs and symptoms: signs and symptoms: body weight: body weight changes: weight gain research

PUBMED ID PMID:

MEDLINE DATE:

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical psychopharmacology

VOLUME: 27

Page Numbers: 365-8

Journal Abbreviation:

ISSN: 0271-0749

DAY: 3

MONTH: Aug

YEAR: 2007

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8109496

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Keywords Mesh Terms:

KEYWORDS: Weight Gain

MESH TERMS: drug effects

Chemical & Substance for Abstract: Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Information

Substance Name: aripiprazole

Registry Number: 129722-12-9

Grant and Affiliation Information for Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.

AFFILIATION: Division of Endocrinology, Stanford University, Stanford, CA, USA. sunhkim@stanford.edu

Country: United States

AGENCY: United States NCRR

GRANT: M01-RR00070

ACRONYM: RR

MEDLINETA: J Clin Psychopharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study Related Publications

• 1-Aminocyclopropane-1-carboxylate deaminase from Pseudomonas putida UW4 facilitates the growth of canola in the presence of salt.
• Adjuvant therapy of primary breast cancer. Closing summary and outlook.
• Breast CT.
• Causation: a loosely founded concept in epidemiology.
• Clinical trials and external validity.
• Closing in on the Puzzle of ONJ.
• Comorbidities in older patients with HIV: a retrospective study.
• Double-contrast barium enema for colorectal cancer screening: a review of the issues and a comparison with other screening alternatives.
• Effect of somatic mutation on DNA binding properties of anti-DNA autoantibodies.
• Ethical considerations in publishing research involving human subjects.
• Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion.
• Flexible 3D pharmacophores as descriptors of dynamic biological space.
• Fluorescence microscopy and thin-section electron microscopy.
• Focus your leadership. Preparing for a major incident response.
• Immigration and living arrangements: moving beyond economic need versus acculturation.
• Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
• Marañón, intersexuality and the biological construction of gender in 1920s Spain.
• Measles outbreak in a Vancouver school population: relative risk and vaccine efficacy.
• Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase.
• Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
• Mucolytic enzyme systems; effects of tissue extracts and body fluids, certain steroids, and hemoglobin derivatives on hyaluronidase activity.
• Mucolytic enzyme systems; inhibition of hyaluronidase by human blood serum during the normal menstrual cycle and pregnancy.
• Mucolytic enzyme systems; inhibition of hyaluronidase by serum in human cancer.
• Mucolytic enzyme systems; inhibition of hyaluronidase by serum in infectious diseases.
• Oncology in transition: the pivotal role of the American Society of Clinical Oncology.
• Poverty and human development: a challenge for us all.
• Risky liaisons: what is the relationship between oral conditions and nonoral diseases?
• Role of conformational dynamics in sequence-specific autoantibody*ssDNA recognition.
• Smooth handoffs. How to put the team focus back into ALS/BLS interactions.
• Structural modeling of sequence specificity by an autoantibody against single-stranded DNA.